AMIODARONE PULMONARY TOXICITY - CT FINDINGS IN SYMPTOMATIC PATIENTS

被引:72
作者
KUHLMAN, JE
TEIGEN, C
REN, H
HURBAN, RH
HUTCHINS, GM
FISHMAN, EK
机构
[1] JOHNS HOPKINS MED INST,RUSSELL H MORGAN DEPT RADIOL & RADIOL SCI,BALTIMORE,MD 21205
[2] JOHNS HOPKINS MED INST,DEPT PATHOL,DIV AUTOPSY PATHOL,BALTIMORE,MD 21205
[3] JOHNS HOPKINS MED INST,DEPT GEN SURG,SURG SCI SECT,BALTIMORE,MD 21205
关键词
Amiodarone; Lung; abnormalities; 60.916; 60.917; CT; 60.1211; effects of drugs on; 60.649;
D O I
10.1148/radiology.177.1.2399310
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The computed tomographic (CT) chest scans of 11 patients who developed respiratory or constitutional symptoms while receiving amiodarone therapy were reviewed. CT findings indicative of significant amiodarone exposure included (a) high-attenuation parenchymal-pleural lesions in eight of the 11 patients (73%), and (b) increased liver and/or spleen attenuation in 10 of the 11 patients (91%). Nonspecific pulmonary infiltrates were identified in nine of the 11 patients (82%). Four patients had interstitial infiltrates, four had mixed alveolar and interstitial disease, and one had a conglomerate mass. CT findings of high-attenuation parenchymal-pleural abnormalities are thought to be related to the iodinated chemistry of the drug and its prolonged half-life within the lung. These unique properties of the drug and the use of CT to discriminate attenuation levels provide a means of identifying patients with significant pulmonary accumulation of amiodarone.
引用
收藏
页码:121 / 125
页数:5
相关论文
共 40 条
[1]   AMIODARONE-INDUCED PNEUMONITIS - ASSESSMENT OF RISK-FACTORS AND POSSIBLE RISK REDUCTION [J].
ADAMS, GD ;
KEHOE, R ;
LESCH, M ;
GLASSROTH, J .
CHEST, 1988, 93 (02) :254-263
[2]  
ADAMS PC, 1986, Q J MED, V59, P449
[3]   AMIODARONE-INDUCED HYPERSENSITIVITY PNEUMONITIS - EVIDENCE OF AN IMMUNOLOGICAL CELL-MEDIATED MECHANISM [J].
AKOUN, GM ;
GAUTHIERRAHMAN, S ;
MILLERON, BJ ;
PERROT, JY ;
MAYAUD, CM .
CHEST, 1984, 85 (01) :133-135
[4]   PHARMACOKINETICS OF AMIODARONE AFTER INTRAVENOUS AND ORAL-ADMINISTRATION [J].
ANDREASEN, F ;
AGERBAEK, H ;
BJERREGAARD, P ;
GOTZSCHE, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 19 (04) :293-299
[5]   COMPUTED-TOMOGRAPHY OF AMIODARONE PULMONARY TOXICITY [J].
BUTLER, S ;
SMATHERS, RL .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1985, 9 (02) :375-376
[6]   SPECULATION ON THE MECHANISM FOR AMIODARONE-INDUCED PNEUMONITIS [J].
CAMUS, P ;
JEANNIN, L .
RADIOLOGY, 1984, 150 (01) :279-280
[7]  
COOPER JAD, 1986, AM REV RESPIR DIS, V133, P488
[8]  
COSTAJUSSA FR, 1984, J PATHOL, V143, P73
[9]   ELECTRON-MICROSCOPIC DEMONSTRATION OF LYSOSOMAL INCLUSION-BODIES IN LUNG, LIVER, LYMPH-NODES, AND BLOOD LEUKOCYTES OF PATIENTS WITH AMIODARONE PULMONARY TOXICITY [J].
DAKE, MD ;
MADISON, JM ;
MONTGOMERY, CK ;
SHELLITO, JE ;
HINCHCLIFFE, WA ;
WINKLER, ML ;
BAINTON, DF .
AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) :506-512
[10]   LUNG-DISEASE CAUSED BY AMIODARONE, A NEW ANTIARRYTHMIC AGENT [J].
GEFTER, WB ;
EPSTEIN, DM ;
PIETRA, G ;
MILLER, WT .
RADIOLOGY, 1983, 147 (02) :339-344